«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 02

Page:

300-304

Research Field:

Publishing date:

Info

Title:

Clinical features and survival analysis of metabolic syndrome after allogeneic hematopoietic stem cell transplantation

Author(s):

ZENG Jiangli¹; CHENG Juan¹; 2

1.The First Clinical College of Lanzhou University,Gansu Lanzhou 730000,China;2.Department of Hematology,the First Hospital of Lanzhou University,Gansu Lanzhou 730000,China.

Keywords:

hematopoietic stem cell transplantation; metabolic syndrome; high-density lipoprotein; triglycerides; fasting glucose

PACS:

R733

DOI:

10.3969/j.issn.1672-4992.2024.02.018

Abstract:

Objective:To analyze the clinical features,influencing factors,and survival of patients about metabolic syndrome (MS) after HSCT,and explore the impact of metabolic syndrome on transplanted patients as a complication after HSCT by collating clinical data of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a single center.Methods:The clinical data of 73 hematological patients who underwent allo-HSCT at our center from July 2015 to September 2022 were collected,and the clinical features,influencing factors and and survival of metabolic syndrome at 1 month after allo-HSCT were retrospectively analyzed.Results:73 allo-HSCT patients developed metabolic syndrome 1 month after allo-HSCT were 32 cases,clinically characterized by high triglycerides,low-density lipoprotein and high blood glucose.The clinical data of allo-HSCT patients were analyzed by univariate analysis,and the results of univariate analysis showed that pre-transplantation high blood glucose and post-transplantation bilirubin levels had an effect on the occurrence of metabolic syndrome.Multifactorial analysis showed post-transplant bilirubin level on the development of metabolic syndromehad an effect.Survival analysis showed that the presence or absence of post-transplant metabolic syndrome had no effect on the overall survival of the patients.Conclusion:In this study,we found that the incidence of metabolic syndrome at 1 month after HSCT was 43.84% and that post-transplant bilirubin level was an influential factor in HSCT-MS.Clinical screening and prevention of metabolic-related factors in HSCT patients should be strengthened in order to improve the long-term survival of HSCT patients.

References:

［1］ DEFILIPP Z,DUARTE RF,SNOWDEN JA,et al.Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation:screening and preventive practice recommendations from CIBMTR and EBMT ［J］.Bone Marrow Transplantation,2017,52(2):173-182.
［2］ MCMILLEN KK,SCHMIDT EM,STORER BE,et al.Metabolic syndrome appears early after hematopoietic cell transplantation ［J］.Metabolic Syndrome and Related Disorders,2014,12(7):367-371.
［3］ VINETTE B,MRAD H,EL-AKHRAS A,et al.Synthesis of self-management strategies used by young adults who have undergone hematopoietic stem cell transplantation:A narrative review ［J］.Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique,2021,31(4):470-475.
［4］ OUDIN C,BERBIS J,BERTRAND Y,et al.Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort:a comparison with controls from the French population ［J］.Haematologica,2018,103(4):645-654.
［5］ YI JC,SULLIVAN B,LEISENRING WM,et al.Who enrolls in an online cancer survivorship program? Reach of the INSPIRE randomized controlled trial for hematopoietic cell transplantation survivors ［J］.Biology of Blood and Marrow Transplantation:Journal of the American Society for Blood and Marrow Transplantation,2020,26(10):1948-1954.
［6］ CHEMAITILLY W,COHEN LE,MOSTOUFI-MOAB S,et al.Endocrine late effects in childhood cancer survivors ［J］.Journal of Clinical Oncology:Official Journal of the American Society of Clinical Oncology,2018,36(21):2153-2159.
［7］ RAGBOURNE SC,CROOK MA.Metabolic syndrome in long-term survivors of hematopoietic stem-cell transplantation ［J］.Clinical Lymphoma,Myeloma & Leukemia,2017,17(6):340-346.
［8］ PARIS C,YATES L,LAMA P,et al.Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents ［J］.Pediatric Blood & Cancer,2012,59(2):306-310.
［9］ KLOEHN J,BRODT G,ERNST J,et al.Analysis of risk factors for hepatic sinusoidal obstruction syndrome following allogeneic hematopoietic stem cell transplantation in pediatric patients ［J］.Journal of Cancer Research and Clinical Oncology,2022,148(6):1447-1455.
［10］ MAJHAIL NS,FLOWERS ME,NESS KK,et al.High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation ［J］.Bone Marrow Transplantation,2009,43(1):49-54.
［11］ OUDIN C,SIMEONI MC,SIRVENT N,et al.Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia ［J］.Blood,2011,117(17):4442-4448.
［12］ FRISK P,ARVIDSON J,LARSSON M,et al.Risk factors for cardiovascular disease are increased in young adults treated with stem cell transplantation during childhood ［J］.Pediatric Transplantation,2012,16(4):385-391.
［13］ GUNER OZENEN G,AKSOYLAR S,GOKSEN D,et al.Metabolic syndrome and risk factors after hematopoietic stem cell transplantation in children and adolescents ［J］.Journal of Pediatric Endocrinology & Metabolism:JPEM,2021,34(4):485-493.
［14］ BHATIA S,DAI C,LANDIER W,et al.Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades:A blood or marrow transplant survivor study report ［J］.JAMA Oncology,2021,7(11):1626-1634.
［15］ BIZZARRI C,PINTO RM,CICCONE S,et al.Early and progressive insulin resistance in young,non-obese cancer survivors treated with hematopoietic stem cell transplantation ［J］.Pediatric Blood & Cancer,2015,62(9):1650-1655.
［16］ LU Y,MA X,PAN J,et al.Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation ［J］.Lipids in Health and Disease,2022,21(1):65.
［17］ GREENFIELD DM,SALOOJA N,PECZYNSKI C,et al.Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults:an EBMT cross-sectional non-interventional study ［J］.Bone Marrow Transplantation,2021,56(11):2820-2825.

Memo

Memo:

甘肃省药品监督管理局科研资助项目（编号：2021GSMPA009）;甘肃省卫生行业项目(编号：GSWSKY2021-002)

Common functions

Last Update: 1900-01-01